



Review decision - July 2016

Review decision

Published: 5 July 2016

www.nice.org.uk

Review of NICE Technology Appraisal Guidance No.288; Dapagliflozin for the treatment of type 2 diabetes (recommendations 1.1 and 1.2)

Decision to defer the review

In [August 2015](#), the decision was made that recommendation 1.3 from TA288 should be updated in a Single Technology Appraisal. An appraisal for this indication is now [in development](#) and has an anticipated publication date of January 2017.

At this time it was agreed that the consideration of a review of recommendations 1.1 and 1.2 should be deferred until the publication of the forthcoming clinical guideline for the management of type 2 diabetes. This clinical guideline (NG28) was published in [December 2015](#) and the wording of recommendation 1.1 from TA288 was subsequently re-worded to reflect changes made in the new clinical guideline.

Recommendations 1.1 and 1.2 consider the use of dapagliflozin as dual therapy and a combination therapy options. There are two other published appraisals for type 2 diabetes that look at dual therapy and combination therapy and it would be more efficient to consider these topics in a single review proposal.

Consequently we have decided to defer the consideration of the review until **May 2017**, when recommendations 1.1 and 1.2 of TA288 will be considered for review alongside TA315; Canagliflozin in combination therapy for treating type 2 diabetes and TA336; Empagliflozin for treating type 2 diabetes.